Although we focused on the CXCL16/CXCR6 axis as a potential mechanism for T cell blockade at tumor margins, proposing the disruption of this axis by blocking glycolysis in CXCL16+ glyCAF54,55, future studies may delve into more targeted interventions. Here, CXCR6 is linked to neoplasm.